FDX1 affects the prognosis of lung cancer by altering the expression of cuproptosis-related signature (GLS, PDHA1, PDHB, MTF1, and DLAT), which more strongly confirms that the prognosis of lung cancer patients is closely related to the occurrence of cuproptosis. Here, FDX1 is linked to lung carcinoma.